HPV初筛联合LBC分流的宫颈癌筛查效能与卫生经济学评价

MRP

Medical Research and Practice

2993-96902993-9704

Art and Technology

10.61369/MRP.2026080016

Article

HPV初筛联合LBC分流的宫颈癌筛查效能与卫生经济学评价https://artdesignp.com/journal/MRP/4/8/10.61369/MRP.2026080016古岳东,黄秀霞,颜丽香

2026

2026-08-20

目的评估高危型人乳头瘤病毒（HPV）初筛联合液基细胞学检查（LBC）分流策略在宫颈癌筛查中的分流效能及卫生经济学价值。方法连续纳入2023年1月至2025年12月期间参与河源市免费“两癌”筛查的124,508名35～64岁户籍女性，采用HPV/LBC“一管法”进行检测。筛查路径为：HPV16/18阳性者直接转诊阴道镜；其他12种高危型HPV阳性者依据LBC结果（以ASC-US为阈值）分流转诊。以阴道镜下活检组织病理学诊断为金标准，主要终点为宫颈上皮内瘤变2级及以上（CIN2+）及CIN3+。采用阳性预测值（PPV）、阴道镜转诊率及检出1例病变所需阴道镜数（NNC）等指标，量化评估LBC分流策略的效能。结果高危型HPV总体阳性率为11.70%（14,564/124,508）。联合筛查策略总体阴道镜转诊率为4.81%（5,984/124,508），共检出924例CIN2+及132例CIN3+病变。在非16/18型高危HPV阳性人群中，引入LBC分流后，阴道镜转诊率从理论上的10.01%降至3.12%，NNC从26.07降至3.85，阴道镜资源利用效率提升约6.8倍；分流后实际活检人群的CIN2+ PPV（25.94%）与HPV16/18阳性组（25.80%）持平。结论基于大样本真实世界数据验证，“HPV初筛+LBC分流”策略在实现高级别病变高检出的同时，显著降低了阴道镜转诊负荷，是契合我国卫生经济学国情的宫颈癌筛查资源优化模型，适宜在消除宫颈癌行动中推广应用。子宫颈肿瘤,人乳头瘤病毒,液基细胞学检查,卫生经济学评价,一管法

[1]SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3):209-249.[2] 李静然, 吴瑞芳, 魏丽惠, 等. 阴道自取样高危型人乳头瘤病毒检测用于子宫颈癌筛查的中国专家共识[J]. 中国妇产科临床杂志, 2024,25(06):563-568.[3]HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024,4(1):47-53.[4]WALBOOMERS J M, JACOBS M V, MANOS M M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J]. J Pathol, 1999,189(1):12-19.[5]DE SANJOSE S, QUINT W G, ALEMANY L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study[J]. Lancet Oncol, 2010,11(11):1048-1056.[6]SNIJDERS P J F, STEENBERGEN R D M, HEIDEMAN D A M, et al. HPV-mediated cervical carcinogenesis: concepts and clinical implications[J]. J Pathol, 2006,208(2):152-164.[7] 李明珠, 李静然, 李晓, 等. 中国子宫颈癌筛查指南（二）[J]. 肿瘤综合治疗电子杂志, 2025,11(03):1-12.[8]PERKINS R B, GUIDO R S, CASTLE P E, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors[J]. J Low Genit Tract Dis, 2020,24(2):102-131.[9]HALL M T, HYATT A, SMITH M A, et al. Elimination of cervical cancer: the impact of HPV vaccination, primary HPV screening, and expanded access to cancer treatment services[J]. Mol Aspects Med, 2026,107:101423.[10] 中华预防医学会肿瘤预防与控制专业委员会, 中国医师协会妇产科医师分会阴道镜与宫颈病变专业委员会, 中国优生科学协会阴道镜和子宫颈病理学分会, 等. 人乳头状瘤病毒核酸检测用于宫颈癌筛查中国专家共识(2022)[J]. 中华医学杂志, 2023,103(16):1184-1195.[11]SINGH D, VIGNAT J, LORENZONI V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197-e206[12]SON Y, HONG S, JANG W, et al. Global, regional, and national burden of cervical cancer in 2022 and projections to 2050: a population-based analysis of GLOBOCAN. Int J Gynecol Cancer. 2026;36(1):102751[13]LUU X Q, JUN J K, SUH M, et al. Cervical Cancer Screening, HPV Vaccination, and Cervical Cancer Elimination[J]. JAMA network open, 2025,8(8):e2526683[14] 任文辉, 赵雪莲, 赵方辉. 全球宫颈癌筛查指南制定现状的系统综述[J]. 中华医学杂志, 2021,101(24):1882-1889.[15]SHANSHAN C, JING C, TAO X. HPV infection status among women of all ages in Jinshan District, Shanghai. J Int Med Res. 2024;52(11):3000605241291754.[16]GOTTSCHLICH A, SMITH LW, HONG Q, et al. HPV, Cytology, and Cotest Cervical Cancer Screening and the Risk of Precancer. JAMA Netw Open. 2026;9(3):e261304